In the past six decades, innovation and technology in the pharma industry have improved global health to a big extent. And intellectual property has played the main role in this progress. Discovering a new drug, organizing clinical trials and gaining regulatory approval cost around US$1 billion. As per the studies, less than 1% of the compounds inspected in pre-clinical stages are sent for testing in human beings and among the compounds that enter clinical trials, only 22% reach the development stage and get regulatory approval. Though the R&D outlays can be reduced by 64% without patents, it will jeopardize the innovation process as well as the well-being of the patients.